Related content

Antiparkinsonian Action of a Opioid Agonist in Rodent and Primate Models of Parkinson's Disease

By Hille C.J.   Fox S.H.   Maneuf Y.P.   Crossman A.R.   Brotchie J.M.  

Experimental Neurology, Vol. 172, Iss. 1, 2001-11 ,pp. : 189-198

Elsevier

Access to resources Recommend Favorite

Effects of adenosine and adenosine A_2A receptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy

By Kumar Sokindra   Arun K. H. S.   Kaul Chaman L.   Sharma Shyam S.  

Neurological Research, Vol. 27, Iss. 1, 2005-01 ,pp. : 60-66

Maney Publishing

Access to resources Recommend Favorite

Combined Use of the Adenosine A 2A Antagonist KW-6002 with l-DOPA or with Selective D1 or D2 Dopamine Agonists Increases Antiparkinsonian Activity but Not Dyskinesia in MPTP-Treated Monkeys

By Kanda T.   Jackson M.J.   Smith L.A.   Pearce R.K.B.   Nakamura J.   Kase H.   Kuwana Y.   Jenner P.  

Experimental Neurology, Vol. 162, Iss. 2, 2000-04 ,pp. : 321-327

Elsevier

Access to resources Recommend Favorite

Raclopride-induced motor consolidation impairment in primates: role of the dopamine type-2 receptor in movement chunking into integrated sequences

By Levesque M.   Bedard M.   Courtemanche R.   Tremblay P.   Scherzer P.   Blanchet P.  

Experimental Brain Research, Vol. 182, Iss. 4, 2007-10 ,pp. : 499-508

Springer Publishing Company

Access to resources Recommend Favorite

Quetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models

By Oh J.D.   Bibbiani F.   Chase T.N.  

Experimental Neurology, Vol. 177, Iss. 2, 2002-10 ,pp. : 557-564

Academic Press

Access to resources Recommend Favorite